ACHE and Alzheimer disease: The reduction of AChE activity by the administered encapsulated form of catechin in chitosan‐alginate NPs containing lower amounts of catechin (10 mg/kg) compared to the free catechin (50 mg/kg) indicates the high efficacy of catechin‐loaded chitosan‐alginate NPs for the treatment of AD.